Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Fiorenzo Santoleri, Elena Ranucci, Gaetano La Barba, Irene Colasanto, Matilde Scaldaferri, Francesco Cattel, Francesca Federici, Chiara Rossi, Katiuscia Di Biagio, Anna Rita Scortechini, Felice Musicco, Giancarlo Torquati, Angela Frazzetto, Antonietta Vozza, Caterina de Rosa, Rosaria Lanzillo, Maria Monteverde, Luigia Luciano, Fabrizio Pane, Arianna Pasquazi, Maria Grazia Celeste, Maria Cantonetti, Luca Franceschini, Manuela Rizzo & Alberto Costantini. (2021) Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life. Current Medical Research and Opinion 37:3, pages 477-481.
Read now
Read now
Jorge Cortes, Lynn Huynh, Estella Mendelson, Patricia Brandt, Darshan Dalal, Maral DerSarkissian, Diego Cortina, Sahil Narkhede & Mei Sheng Duh. (2020) Treatment patterns and deep molecular response in chronic phase – chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study. Leukemia & Lymphoma 61:1, pages 98-107.
Read now
Read now
Nanxin Li, Xi Yang, Liangyi Fan, Todor Totev, Annie Guerin, Lei Chen, Subrata Bhattacharyya & George Joseph. (2017) Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data. Journal of Medical Economics 20:4, pages 328-336.
Read now
Read now
B. Douglas Smith, Jun Liu, Dominick Latremouille-Viau, Annie Guerin, Daniel Fernandez & Lei Chen. (2016) Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy. Current Medical Research and Opinion 32:5, pages 817-827.
Read now
Read now
Articles from other publishers (8)
Massimiliano Bonifacio, Vikalp Maheshwari, Diana Tran, Gianluca Agostoni, Kalitsa Filioussi & Ricardo Viana. (2021) Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy. PharmacoEconomics - Open 6:1, pages 95-104.
Crossref
Crossref
Emilia Scalzulli, Giovanni Caocci, Fabio Efficace, Lorenzo Rizzo, Gioia Colafigli, Alessio Di Prima, Sara Pepe, Danilo Alunni Fegatelli, Ida Carmosino, Daniela Diverio, Roberto Latagliata, Giorgio La Nasa, Maurizio Martelli, Robin Foà & Massimo Breccia. (2021) Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients. Annals of Hematology 100:5, pages 1213-1219.
Crossref
Crossref
N. A. Avxentyev, M. Yu. Frolov & A. S. Makarov. (2018) Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia. PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology 11:2, pages 27-37.
Crossref
Crossref
Avaronnan Manuprasad, Prasanth Ganesan, Trivadi S. Ganesan, Venkatraman Radhakrishnan, Manikandan Dhanushkodi, Samson Mani & Tenali Gnana Sagar. (2017) Experience with the Use of Nilotinib in Indian Patients. Indian Journal of Hematology and Blood Transfusion 34:3, pages 443-447.
Crossref
Crossref
Mario Tiribelli, Massimiliano Bonifacio, Gianni Binotto, Alessandra Iurlo, Francesca Cibien, Elena Maino, Anna Guella, Gianluca Festini, Claudia Minotto, Ercole De Biasi, Federico De Marchi, Luigi Scaffidi, Luca Frison, Cristina Bucelli, Marta Medeot, Elisabetta Calistri, Rosaria Sancetta, Manuela Stulle, Nicola Orofino, Mauro Krampera, Filippo Gherlinzoni, Gianpietro Semenzato, Giovanni Pizzolo, Achille Ambrosetti & Renato Fanin. (2018) Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients. Oncotarget 9:18, pages 14219-14227.
Crossref
Crossref
Anna Stępień, Krzysztof Jamroziak, Tomasz Sacha, Dorota Link-Lenczowska, Izabela Florek, Witold Prejzner, Zofia Specht-Szwoch, Małgorzata Całbecka, Marcin Rymko, Marek Dudziński, Paulina Wieszczy, Krzysztof Warzocha & Janina Góra-Tybor. (2016) Retrospektywna analiza skuteczności nilotynibu i dazatynibu w drugiej linii terapii przewlekłej białaczki szpikowej w polskich ośrodkach hematologicznych. Acta Haematologica Polonica 47:3, pages 219-225.
Crossref
Crossref
Shiwei Zhou, Yingying Wang & Jun-Jie Zhu. (2016) Simultaneous Detection of Tumor Cell Apoptosis Regulators Bcl-2 and Bax through a Dual-Signal-Marked Electrochemical Immunosensor. ACS Applied Materials & Interfaces 8:12, pages 7674-7682.
Crossref
Crossref
Jie Ding, Julia Romani, Margarete Zaborski, Roderick A. F. MacLeod, Stefan Nagel, Hans G. Drexler & Hilmar Quentmeier. (2013) Inhibition of PI3K/mTOR Overcomes Nilotinib Resistance in BCR-ABL1 Positive Leukemia Cells through Translational Down-Regulation of MDM2. PLoS ONE 8:12, pages e83510.
Crossref
Crossref